Skip to content
10-Q

Quarterly Report

Aurinia Pharmaceuticals Inc. AUPH

0001600620-25-000049

← back to feed
Filed
May 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 8, 2025 135.1M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $68.41M
Current Liabilities Q1 2025 · Dec 31, 2024 $97.76M
Total Liabilities Q1 2025 · Mar 31, 2025 $154.66M
Total Liabilities Q1 2025 · Dec 31, 2024 $173.17M
Current Assets Q1 2025 · Mar 31, 2025 $405.76M
Current Assets Q1 2025 · Dec 31, 2024 $446.6M
Total Assets Q1 2025 · Mar 31, 2025 $504.85M
Total Assets Q1 2025 · Dec 31, 2024 $550.65M
Shares Diluted Q1 2025 · Mar 31, 2024 144.01M sh
Stock Repurchased Q1 2025 · Mar 31, 2024 $12.3M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$18.6M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $63.91M
Stockholders Equity Q1 2025 · Mar 31, 2024 $359.48M
Stockholders Equity Q1 2025 · Dec 31, 2023 $377.95M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.07
Eps Basic Q1 2025 · Mar 31, 2024 −$0.07
Rd Expense Q1 2025 · Mar 31, 2024 $5.55M
Net Income Q1 2025 · Mar 31, 2024 −$10.75M
Operating Income Q1 2025 · Mar 31, 2024 −$13.25M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $7.75M
Revenue Q1 2025 · Mar 31, 2024 $50.3M